S&P Futures
4,158.50-4.00(-0.10%)Dow Futures
33,917.00-6.00(-0.02%)Nasdaq Futures
13,975.50-38.50(-0.27%)
Seagen Inc. (SGEN)
Chart Events
Performance Outlook
| Previous Close | 144.20 |
| Open | 145.19 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 144.94 - 151.88 |
| 52 Week Range | 131.74 - 213.94 |
| Volume | 1,108,419 |
| Avg. Volume | 1,184,560 |
| Market Cap | 27.131B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | 44.40 |
| EPS (TTM) | 3.37 |
| Earnings Date | Apr 29, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 192.06 |
Fair Value
Related Research
- Business Wire
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of Oct 10, 2021. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) directed to tissue factor (TF), a cell-surface protein expressed on multiple solid tumors including cervical cancer, and is associated with tumor growth, angiogenesis, metastasis and poor prognosis.1
- Business Wire
Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of October 10, 2021. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) directed to tissue factor (TF), a cell-surface protein expressed on multiple solid tumors including cervical cancer, and is associated with tumor growth, angiogenesis, metastasis and poor prognosis.1
- Business Wire
Seagen to Highlight Data from Novel Targeted Therapies at AACR
Seagen Inc. (Nasdaq: SGEN) today announced that preclinical data from its pipeline of novel targeted oncology drugs will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 10-15, 2021. The oral and poster presentations will highlight several early-stage programs utilizing Seagen’s leading antibody-drug conjugate (ADC) technology as well as its proprietary sugar-engineered antibody (SEA) technology.
